传统流感疫苗影响小鼠通用流感疫苗的表现
研究在具有传统疫苗接种史的小鼠中测试候选通用流感疫苗A/NP+M2-rAd。雌性BALB/c小鼠先接种IIV、DT或LAIV,再接种通用疫苗,以ELISA和ELISPOT评估免疫应答,并以A/FM/1/47(H1N1)攻击检测保护。结果显示不同既往接种可增强、抑制或不影响通用疫苗表现。
要点
- 既往接种Afluria IIV和LAIV的小鼠对A/NP的抗体和T细胞应答高于无既往接种小鼠。
- 既往接种Fluvirin IIV部分抑制通用疫苗,但仍提供相当保护。
- 既往接种Fluzone IIV和DT对A/NP+M2-rAd表现无影响。
核心结论
- 候选通用疫苗A/NP+M2-rAd在具有不同既往接种史的小鼠中至少部分有效。
- 保护程度和免疫应答性质可能受传统疫苗接种史影响,提示人体中的表现会受到免疫史影响。
研究设计与样本
- 雌性BALB/c小鼠研究:分别给予两剂肌肉注射灭活流感疫苗(IIV)或白喉破伤风类毒素疫苗(DT),间隔一个月;另一组给予两剂鼻内减毒活流感病毒(LAIV)。
- 第二剂后一个月给予通用流感疫苗:表达流感A核蛋白(A/NP)和基质2(M2)的重组腺病毒(A/NP+M2-rAd)。
- 以ELISA和干扰素-γ ELISPOT评估对A/NP和M2的免疫应答,以小鼠适应A/FM/1/47(H1N1)攻击并监测体重下降和生存来检测保护。
主要发现
- 既往接种Afluria IIV和LAIV的小鼠对A/NP的抗体和T细胞应答高于无既往接种小鼠,为A/NP+M2-rAd表现增强的例子。
- 既往接种Fluvirin IIV部分抑制通用疫苗,但不同于传统疫苗,通用疫苗仍提供相当保护。
- 既往接种Fluzone IIV和DT对A/NP+M2-rAd表现无影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Universal influenza vaccines are designed to protect against diverse strains of influenza virus. Preclinical testing of new vaccine candidates is usually done in naïve animals, despite intended use in the human population with its varied immune history including responses to previous vaccinations. As an approach more relevant to human use, we tested a candidate universal influenza vaccine in mice with a history of conventional vaccination. Female BALB/c mice were given two intramuscular doses of inactivated influenza vaccine (IIV) or diphtheria and tetanus toxoids vaccine (DT), one month apart. Another group was given two intranasal doses of live attenuated influenza virus (LAIV). One month after the second dose, mice were given the universal influenza vaccine: recombinant adenoviruses expressing influenza A nucleoprotein (A/NP) and matrix 2 (M2) (A/NP + M2-rAd). Immune responses to universal vaccine antigens A/NP and M2 were assessed by ELISA and interferon-γ ELISPOT. Protection was tested by challenge with mouse-adapted A/FM/1/47 (H1N1) and monitoring for weight loss and survival. Universal vaccine performance was enhanced, inhibited or unaffected by particular prior vaccinations. Mice given Afluria IIV and LAIV had greater antibody and T-cell response to A/NP than mice without prior vaccination, providing examples of enhanced A/NP + M2-rAd performance. Though Fluvirin IIV partially inhibited, the universal vaccine still provided considerable protection unlike conventional vaccination. Fluzone IIV and DT had no effect on A/NP + M2-rAd performance. Thus our results demonstrate that universal vaccine candidate A/NP + M2-rAd was at least partially effective in mice with diverse prior histories. However, the degree of protection and nature of the immune responses may be affected by a history of conventional vaccination and suggests that performance in humans would be influenced by immune history.
引用
- Rowell J, Lo CY, Price GE, et al. Conventional influenza vaccines influence the performance of a universal influenza vaccine in mice. Vaccine. 2017. PMID: 29249542. doi:10.1016/j.vaccine.2017.11.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。